GlassScriptPhysician profile
Frank J Conte
NPI 1962471011
$3,993.29
in general payments reported to CMS, 2019-2025
30 companies · $571 in 2025
The $571 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,499 · 2020: $496 · 2021: $47.81 · 2022: $501 · 2023: $445 · 2024: $433 · 2025: $571.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,449.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,449.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $780.41 | 2019-2025 | Cardiomems, Aveir, Confirm Rx |
| Amgen INC. | $617.96 | 2019-2025 | Repatha, Repatha |
| Boston Scientific Corporation | $352.19 | 2019-2025 | Watchman Flx |
| Pfizer INC. | $339.59 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $310.59 | 2019-2023 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $224.13 | 2019-2025 | Farxiga, Brilinta |
| Heartflow, INC. | $200.67 | 2023-2025 | Ffrct |
| Sanofi-Aventis U.S. LLC | $186.66 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $182.93 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $110.92 | 2023-2024 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $107.18 | 2019-2023 | Camzyos |
| Stryker Corporation | $73.07 | 2025 | Flowtriever |
| Lexicon Pharmaceuticals, INC. | $52.04 | 2023-2024 | Inpefa |
| Otsuka America Pharmaceutical, INC. | $48.03 | 2019 | |
| Medtronic Vascular, INC. | $44.97 | 2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $36.76 | 2019 | |
| Chiesi USA, INC. | $35.10 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $35.00 | 2025 | |
| Amarin Pharma, INC. | $34.60 | 2019-2020 | |
| Philips North America LLC | $33.99 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $31.49 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $27.56 | 2023-2025 | Lifevest |
| Tersera Therapeutics LLC | $22.81 | 2021 | |
| Novo Nordisk INC | $17.27 | 2025 | Wegovy |
| Braemar Manufacturing, LLC | $16.26 | 2019 | |
| Edwards Lifesciences Corporation | $15.96 | 2019 | |
| Baxter Healthcare | $15.08 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| Esperion Therapeutics, INC. | $14.97 | 2024 | Nexletol |
| Gilead Sciences, INC. | $14.78 | 2019 | |
| Cvrx, INC. | $10.32 | 2025 | Barostim Neo System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frank Conte listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.